MedinCell S.A.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceuti…
Biotechnology
FR, Jacou [HQ]
Ratios
9 Records · Starting from 2015Margins, Growth Rates In %
| Ratio | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | 95.97 | 89.63 | 96.61 | 30.08 | 66.02 | 82.27 | 203.86 | 138.08 | 101.42 | |
| Profit Margin | 7.56 | -41.73 | -148.66 | -1,364.31 | -838.53 | -231.93 | -606.50 | -323.69 | -277.21 | |
| Operating Margin | 5.11 | -42.06 | -114.60 | -1,075.26 | -787.76 | -232.48 | -688.17 | -281.49 | -264.09 | |
|
EPS Growth
|
- - | -681.40 | -164.00 | -72.73 | -4.39 | 27.73 | -16.28 | -27.00 | 30.71 | |
| EPS EUR | 4.30 | -25.00 | -66.00 | -114.00 | -119.00 | -86.00 | -100.00 | -127.00 | -88.00 | |
| Return on Assets (ROA) | 5.57 | -15.31 | -37.75 | -51.83 | -87.58 | -29.85 | -55.99 | -109.10 | -67.77 | |
| Return on Equity (ROE) | 50.16 | 152.70 | 81.23 | -315.35 | 149.86 | -208.02 | 185.52 | 75.68 | 61.33 | |
| Return on Invested Capital (ROIC) | 13.42 | -14.14 | -39.90 | -46.56 | -127.80 | -30.92 | -76.97 | -193.54 | -118.18 | |
| Solvency | ||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | -100 | -100 | |
| Debt/Assets | 38.69 | 89.00 | 122.26 | 71.18 | 121.05 | 67.04 | 100.66 | 188.02 | 159.58 | |
| Debt/Equity | 348.55 | -887.86 | -263.07 | 433.05 | -207.14 | 467.19 | -333.51 | -130.43 | -144.43 | |
| Debt/EBITDA | 467.77 | -772.59 | -346.64 | -37.78 | -120.02 | 4.24 | -104.67 | -195.78 | -212.21 | |
|
Debt/Capitalization
|
77.71 | 112.69 | 161.33 | 81.24 | 193.34 | 82.37 | 142.82 | 428.65 | 325.09 | |
| Long-Term Debt/Capitalization | 68.06 | 113.29 | 169.68 | 79.09 | 204.14 | 81.06 | 564.59 | -38.28 | 440.88 | |
| Interest Debt per Share EUR | 0.31 | 1.53 | 2.28 | 1.69 | 1.75 | 2.10 | 1.87 | 2.35 | 2.24 | |
| Debt Growth | - - | 379.06 | 49.71 | -12.78 | 25.15 | 28.11 | 9.57 | 21.51 | 2.17 | |
| Liquidity | ||||||||||
| Current Ratio | 100.52 | 254.43 | 167.70 | 334.83 | 268.62 | 414.15 | 89.10 | 34.31 | 165.54 | |
| Quick Ratio | 100.52 | 240.23 | 151.46 | 317.67 | 268.62 | 414.15 | 89.10 | 34.31 | 206.32 | |
| Cash Ratio | 8.98 | 69.68 | 108.09 | 273.89 | 126.89 | 324.23 | 51.30 | 11.34 | 118.18 | |
| Operating Cash Flow Ratio | - - | - - | - - | -200 | -200 | -100 | - - | - - | - - | |
| Turnover | ||||||||||
| Inventory Turnover | 33,200,000.00 | 113.61 | 16.50 | 75.64 | - - | - - | - - | - - | 1.91 | |
| Receivables Turnover | 211.95 | 178.59 | 185.91 | 43.20 | 64.94 | 177.84 | 71.88 | 80.56 | 134.53 | |
| Payables Turnover | 20.80 | 41.20 | 8.93 | 61.38 | 30.90 | 49.09 | -142.46 | -90.16 | -6.92 | |
|
Asset Turnover
|
73.68 | 36.68 | 25.39 | 3.80 | 10.44 | 12.87 | 9.23 | 33.71 | 24.45 | |
| Fixed Turnover | 549.53 | 343.38 | 236.26 | 43.49 | 70.35 | 212.46 | 58.17 | 155.19 | 166.21 | |
| Coverage | ||||||||||
| Interest Coverage | 331.50 | -275.02 | -399.24 | -729.48 | -1,057.77 | -531.15 | -1,526.36 | -707.96 | -516.63 | |
| Asset Coverage | 100 | - - | - - | 100 | - - | 100 | - - | - - | - - | |
| Cash Flow Coverage (CFGR) | 1.57 | -16.39 | -17.50 | -58.93 | -42.35 | -36.58 | -50.22 | -46.08 | -20.22 | |
| EBITDA Coverage | 600 | -100 | -300 | -700 | -900 | -400 | -1,400 | -600 | -400 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | 100 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||
| Dividend Yield | - - | 16.78 | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | 0.59 | -3.36 | -9.02 | -18.58 | -19.95 | -7.36 | -13.45 | -12.95 | -9.04 | |
|
Price/Earnings (P/E)
|
170.9460 | -29.7471 | -11.0828 | -5.3824 | -5.0118 | -13.5847 | -7.4378 | -7.7194 | -11.0668 | |
| Price/Earnings Growth (PEG) | - - | 4.37 | -6.76 | -7.40 | -114.27 | 48.99 | -45.69 | -28.59 | 36.04 | |
|
Price/Book (P/B)
|
8,574.87 | -4,542.42 | -900.22 | 1,697.30 | -751.09 | 2,825.89 | -1,379.86 | -584.24 | -678.74 | |
| Price/Tangible Book (P/TB) | 8,574.87 | -4,542.42 | -900.22 | 1,697.30 | -751.09 | 2,825.89 | -1,379.86 | -584.24 | -678.74 | |
| Price/Sales (P/S) | 1,291.65 | 1,241.41 | 1,647.61 | 7,343.20 | 4,202.61 | 3,150.73 | 4,511.03 | 2,498.73 | 3,067.87 | |
|
Price/Cash Flow (P/CF)
|
156,365.31 | -3,122.00 | -1,954.91 | -665.09 | -856.25 | -1,653.64 | -823.92 | -972.03 | -2,324.19 | |
| Price/Free CF (P/FCF) | -9,701.50 | -2,027.74 | -1,603.77 | -635.04 | -803.39 | -1,571.14 | -757.18 | -934.28 | -2,113.09 | |
| Price/Operating CF (P/OCF) | 156,365.31 | -3,122.00 | -1,954.91 | -665.09 | -856.25 | -1,653.64 | -823.92 | -972.03 | -2,324.19 |